Four new meds recommended for approval by EMA's CHMP

Following its November 2022 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended four medicines for approval, one a biosimilar, two generics and the other a coronavirus vaccine.

The committee adopted a positive opinion for a biosimilar medicine, Kauliv (teriparatide), from Strides Pharma Cyprus, for the treatment of osteoporosis, a health condition that weakens bones, making them fragile and more likely to break.

A generic medicine, Pirfenidone Viatris (pirfenidone), from Viatris (Nasdaq: VTRS) received a positive opinion for the treatment of idiopathic pulmonary fibrosis, a chronic and progressive condition in which the lungs become scarred and breathing becomes increasingly difficult.